Novel nanoparticles of cisplatin:in vitro and in vitro antitumor activity

LI Ru-tian,YU Li-xia,LI Xiaolin,LIU Bao-rui
DOI: https://doi.org/10.3969/j.issn.1674-4136.2009.01.012
2009-01-01
Chinese Journal of Surgical Oncology
Abstract:Objective To prepare cisplatin-loaded nanoparticles with bi-block copolymer mPEG-PCL and PCL,and evaluate their antitumor effect in vitro and in vivo.Methods mPEG-PCL and HO-PCL were synthesized by ring-opening polymerization method and the nanoperticles were prepared by developed w/o/w double emulsion method.The in vitro cytotoxicity of cisplatin-loaded nanoparticles and toxicity of the blank nanoparticles were evaluated by MTT assay.We assess the antitumor efficacy of nanoparticles in vivo and free cisplatin on mice implanted subcutaneously with H22 cells.The antitumor effect of the two formulations was determined by tumor volume measurement,and the toxicity was studied by body weight measurement.Results mPEG-PCL and PCL are synthesized with desired molecular weight.The diameter of cisplatin-loaded nanoparticles is(370.3 ±2.5) nm.The encapsulation efficiency and drug loading content are 77.4%and 4.72%respectively.In vitro the release presents a sustain-release pattern.The nanoparticles exhibites similar cytotoxicity compared to free eisplatin while the blank nanoparticles are non-loxic to the cell line.According to in vivo studies in vivo,the cisplatin-loaded nanoperticles showed better antitumor effect than free eisplatin at the same dosage.As to the side effect,mice in the group of nanoparticles in vitro showed milder body loss.Conclusions the nanoparticles synthesized wilh mPEG-PCL and PCL was characterized by suslained-telaease.The antitumor effect of nanoparticles in vitro was similar to free eisplatin.According to study in vivo,the cisplatin-loaded nanoperticles showed better antitumor effect than free eisplatin at the same dosage.As to the side effect,mice in the group of nanoparticles showed milder body loss.The above findings indicate the potential of this nanoparticles as carrier for cisplatin.
What problem does this paper attempt to address?